Natiijooyinka xarun badan wajiga III tijaabada caafimaadku waxay muujisay in haddii bukaanka waayeelka ah ee qaba leukemia-da 'lymphocytic leukemia' Cll ) waxaa lagu daaweeyaa daawada cusub ee la bartilmaameedsaday ee ibrutinib marka la barbardhigo nidaamkii hore ee sida caadiga ah wax ku oolka ahaa-bendamustine oo ay weheliso rituximab Heerka horumarka cudurka ee mAb aad ayuu hoos ugu dhacay, taas oo sidoo kale muujineysa in rituximab oo lagu daro ibrutinib aysan keenin doonin waxtar dheeri ah ibrutinib kaligeed.
CLL waa kansarka ugu badan ee leukocyte ee waayeelka. Sannadkii 2016, US FDA ayaa oggolaatay ibrutinib inay tahay daaweynta ugu horreysa ee CLL. Daraasadihii hore waxay muujiyeen in ibrutinib uu ka waxtar badan yahay daawo kale oo kiimiko ku daweysan oo loo yaqaan 'chlorambucil', laakiin daraasado lama barbardhigin ibrutinib iyo bendamustine iyo rituximab.
Tijaabadu waxay qortay 547 bukaan da 'ah oo da'adoodu dhexdhexaad tahay 71 sano. 1/3 ayaa si aan kala sooc lahayn loogu qoondeeyay inay helaan bendamustine Tingjia Li rituximab, 1/3 waxaa aqbalay Lu rituximab oo loogu talagalay Nijia Li, 1/3 kaligeed waxaa leh Lu imatinib. Cilmi baarayaashu waxay dabagal ku sameeyeen dhexdhexaad dhexdhexaad ah oo ah 38 bilood.
Marka la barbardhigo bendamustine plus rituximab (74% at 2 years), ibrutinib plus rituximab (88% at 2 years) and ibrutinib alone (2 Sannadka, 87%) bukaanku waxay leeyihiin heerka badbaadada aan horumarka lahayn ee dheer (ujeeddada koowaad ee daraasadda) ). Si kastaba ha noqotee, daraasaddu ma helin wax farqi ah oo ku saabsan heerarka guud ee badbaadada saddexda koox ee 2 sano.
Marka loo barbardhigo helitaanka ibrutinib kaligiis, ku darista rituximab ibrutinib uma muuqan inay horumarineyso saadaasha. Guud ahaan, bukaanku sifiican ayey uga jawaabeen dhamaan sedexda xulasho ee daaweynta. Heerka jawaabta guud ee bukaanada qaata bendamustine oo lagu daray rituximab waxay ahayd 81%, bukaanada qaata ibrutinib oo lagu daray rituximab ilaa 93% bukaanka Lu shaqsi ahaan qaata daaweynta imatinib wuxuu ahaa 94%.
In kasta oo xaddiga tirtirka dhammaystirka leukemia iyadoo la adeegsanayo bendamustine lagu daray rituximab uu ka sarreeyay, haddana farqigaasi uma turjummin heerar badbaado oo wanaagsan ama heerarka soo noqoshada oo hooseeya. Marka ka taxaddar marka aad dooranayso daroogada.
Si kastaba ha noqotee, ibrutinib wuxuu la xiriiraa waxyeelooyin muhiim ah sida fibrillation-ka wadnaha iyo wadnaha oo aan caadi ahayn oo kordhiya halista istaroogga iyo cudurrada kale ee wadnaha iyo xididdada. Bukaanku wuxuu fiiro gaar ah u leeyahay la socoshada xaaladda wadnaha inta lagu jiro isticmaalka.
https://medicalxpress.com/news/2018-12-ibrutinib-outperforms-chemoimmunotherapy-older-patients.html
